These observations make Lrrk1 an attractive antiresorptive drug target because Lrrk1 KO mice have normal membranous bone, and inhibiting Lrrk1 may not interfere with osteoclast-coupled bone formation in the maxilla and mandible or cause osteonecrosis of the jaw. This evidence concerns the gene LRRK1 and osteonecrosis.